24/7 Patient Assistance: 760-405-8205

Claire Verschraegen, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

  • Bio & Insurance Information

    An original of Bruxelles, Belgium, Dr. Verschraegen graduated from the Universite Libre de Bruxelles in Belgium in 1982. Dr. Verschraegen chose a specialty in Internal Medicine and Oncology and finished her studies at the same university in 1987. She was a researcher at the Stehlin Foundation for Cancer Research between 1985 and 1988, having been granted a research fellowship. A leading expert in malignant peritoneal mesothelioma, Dr. Verschraegen completed two residencies at University of Texas Science Center and M.D. Anderson Cancer Center. She studied as a fellow in internal medicine at the Clinique L. Caty in Belgium. Dr. Claire Verschraegen has board certifications in medical oncology and internal medicine.

  • Education & Training


    Free University of Brussels



    Universite Libre De Bruxelles - 1982

    Medical School


    University of Texas Science Center and M.D. Anderson Cancer Center



    Clinique L. Caty


  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    The University of Vermont Medical Center

    Languages: English/Spanish

    (800) 358-1144

    111 Colchester Ave

    Burlington, Vermont 05401

    Read More
  • Publications & Memberships

    Dr. Claire Verschraegen has contributed to 5 publications.

    Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality.

    Vinh-Hung V, Verschraegen C. J Natl Cancer Inst. 2004 Jan 21;96(2):115-21. PubMed PMID: 14734701.

    See more >>

    Absence of epidermal growth factor receptor mutations in cervical cancer.

    Arias-Pulido H1, Joste N, Chavez A, Muller CY, Dai D, Smith HO, Verschraegen CF.

    See more >>

    Efficacy and safety of ipilimumab monotherapy in patients

    O'Day SJ1, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD.

    See more >>

    Epidermal growth factor receptor as a biomarker for cervical cancer.

    Soonthornthum T1, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C.

    See more >>

    Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

    Verschraegen CF1, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T.

    See more >>